EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review

被引：1
|
作者：
Enting, D. [1 ]
Januszewski, A. [1 ]
Benepal, T. [1 ]
机构：
[1] St Georges Healthcare NHS Trust, Dept Oncol, London, England
来源：
LUNG CANCER | 2012年 / 75卷
关键词：
D O I：
10.1016/S0169-5002(12)70014-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [41] Epidermal Growth Factor Receptor (EGFR) Mutation Testing in non-small cell lung cancer (NSCLC) patients
    Wallace, Andrew
    Howard, E.
    Dutton, L.
    Elles, R. G.
    Newman, W.
    JOURNAL OF MEDICAL GENETICS, 2010, 47 : S66 - S66
  • [42] Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
    Gu, L.
    Yu, Y.
    Shen, L.
    Yao, F.
    Zhu, C.
    Wang, J.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S603 - S604
  • [43] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [44] A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Lara-Mejia, Luis
    Sanchez-Reyes, Roberto
    Aviles-Salas, Alejandro
    Arrieta-Rodriguez, Oscar
    ONCOLOGY-NEW YORK, 2020, 34 (01): : 21 - 27
  • [45] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [46] Characteristics, treatment patterns and outcomes of patients with small cell lung cancer-A retrospective single institution analysis
    Hermes, Andreas
    Waschki, Benjamin
    Gatzemeier, Ulrich
    Reck, Martin
    LUNG CANCER, 2011, 71 (03) : 363 - 366
  • [47] A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer
    Iwama, E.
    Sakai, K.
    Azuma, K.
    Nosaki, K.
    Harada, D.
    Hotta, K.
    Ohyanagi, F.
    Kurata, T.
    Akamatsu, H.
    Goto, K.
    Fukuhara, T.
    Nakanishi, Y.
    Nishio, K.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2015, 26 : 148 - 149
  • [48] Association of TP53 mutation status with clinical outcomes in patients with EGFR mutated non-small cell lung cancer (NSCLC)
    Ahmed, Saman
    Aggarwal, Charu
    Mick, Rosemarie
    Bauml, Joshua
    Cohen, Roger
    Kadauke, Stephan
    Sterlicchi, Trisha
    Evans, Tracey L.
    Kucharczuk, John C.
    Desphande, Charu
    Morrissette, Jennifer J. D.
    Daber, Robert
    Langer, Corey J.
    CANCER RESEARCH, 2015, 75
  • [49] Evaluation of non-small cell lung cancer (NSCLC) tumour sample requirements for EGFR and KRAS mutation analysis
    Morgan, Shethah
    Donald, Emma
    Ryan, Anderson
    Kockx, Mark
    Verstrepen, Walter
    Tepperberg, James
    ANNALS OF ONCOLOGY, 2011, 22 : 26 - 26
  • [50] Homocysteine levels in newly diagnosed patients with non-small cell lung cancer
    Maguire, J
    Armour, A
    Kelly, V
    Ledson, M
    Smyth, C
    Walshaw, M
    THORAX, 2005, 60 : II55 - II55
12345